Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: A transmission-dynamic modelling study

Highlights • 2-dose girls-only HPV vaccination is likely to be cost-effective if protection is at least 10 years. • A 3rd dose is unlikely to be cost-effective if 2-dose duration of protection is longer than 30 years. • Vaccinating boys is unlikely to be cost-effective unless the cost/dose is substa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2014-10, Vol.32 (44), p.5845-5853
Hauptverfasser:	Laprise, Jean-François, Drolet, Mélanie, Boily, Marie-Claude, Jit, Mark, Sauvageau, Chantal, Franco, Eduardo L, Lemieux-Mellouki, Philippe, Malagón, Talía, Brisson, Marc
Format:	Artikel
Sprache:	eng
Schlagworte:	Allergy and Immunology Anogenital warts Applied microbiology Biological and medical sciences Canada Cervical cancer Cost-Benefit Analysis Cost-effectiveness Female Fundamental and applied biological sciences. Psychology Human papillomavirus Human papillomavirus (HPV) Human viral diseases Humans Immunisation Immunization Immunization Schedule Infectious diseases Male Medical research Medical sciences Microbiology Miscellaneous Models, Economic Papillomavirus Infections - economics Papillomavirus Infections - prevention & control Papillomavirus Vaccines - administration & dosage Programme optimisation Quality-Adjusted Life Years Sensitivity analysis Transmission-dynamic modelling Vaccination - economics Vaccine schedules Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Viral diseases Viral diseases of the genital and urinary system Virology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • 2-dose girls-only HPV vaccination is likely to be cost-effective if protection is at least 10 years. • A 3rd dose is unlikely to be cost-effective if 2-dose duration of protection is longer than 30 years. • Vaccinating boys is unlikely to be cost-effective unless the cost/dose is substantially reduced.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2014.07.099